Valeriya Anbinder
Foot & Ankle Surgery · Brooklyn, NYNPI 1033590112
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,050 of the $3,473 with a category attached, or 87.8%. Gotham Surgical Solutions & Devices, Inc. accounts for 87.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $3,050 and has fallen 99.6% since, to $13 in 2024.
Across 8 payments — averaging $434.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gotham Surgical Solutions & Devices, Inc.$3K
- Stryker$151
- Organogenesis Inc.$123
- Angiodynamics, Inc.$97
- Zyla Life Sciences, Inc.$24
- Fidia Pharma USA Inc.$16
- plus $13 from 1 others
What the payments were for
- Food & beverage$42312%
- Education$3,05088%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gotham Surgical Solutions & Devices, Inc. | 1 | $3,050 |
| Stryker | 2 | $151 |
| Organogenesis Inc. | 1 | $123 |
| Angiodynamics, Inc. | 1 | $97 |
| Zyla Life Sciences, Inc. | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUGMENT INJECTABLE$142
- PuraPly$123
How this compares
$3,473 in reported general payments places this provider in the 60th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 221 | $10,356 |
| Ketoconazole | 103 | $2,057 |
| Ammonium Lactate | 53 | $1,247 |
| Diclofenac Sodium | 23 | $507 |
| Mupirocin | 52 | $492 |
| Terbinafine Hcl | 28 | $385 |
| Clotrimazole | 15 | $264 |
| Triamcinolone Acetonide | 32 | $244 |
| Gabapentin | 36 | $144 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $103 |
| Meloxicam | 36 | $76 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Brooklyn
- Yury RotshteynBrooklyn$43K
- Mario VoloshinBrooklyn$33K
- Bryan MakowerBrooklyn$28K
- Amit GandhiBrooklyn$21K
- Edward AzarBrooklyn$18K
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.